Naslov
Cardiovascular Outcomes Trials in Type 2 Diabetes ; benefit beyond glicemic regulation

Autori
Baretić, Maja

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Knjiga sažetaka-12. Hrvatski kongres o aterosklerozi. / - , 2019, 26-26

Skup
12 Hrvatski kongres o aterosklerozi

Mjesto i datum
Crikvenica, Hrvatska, 16.05.2019. - 18.05.2019

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
cardiovasculao outcomes trials ; type 2 diabetes ; glicemic regulation

Sažetak
Type 2 diabetes mellitus (T2DM) is a debilitating disease that impacts the life expectancy, quality of life, and health of an individual. Cardiovascular disease (CVD) is a common diabetes- associated complication and a principal cause for death in diabetic patients. Individuals with T2DM have significantly higher risk of developing CVD compared to the general population. Food and Drug Administration (FDA) in 2008 indicated that novel compounds being developed for T2DM need to go through different clinical trials to guarantee safety from CVD. The FDA published a report called “Guidance for Industry: Diabetes Mellitus - Evaluating CV Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, ” with demand that novel drugs being licensed for diabetes show no adverse CV effect. Some of the recent trials such as the “Empagliflozin Cardiovascular Outcome Event Trial in T2DM Patients-Removing Excess Glucose” (EMPA- REG OUTCOME), “Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results” (LEADER) and “Trial to Evaluate CV and Other Long- term Outcomes with Semaglutide in Subjects with Type 2 Diabetes” (SUSTAIN6) demonstrated a convincing effect on CVD outcomes. Some classes of drugs demonstrate cardiovascular protection, some of them may be a result of a class effect, and some differences might be based on the population enrolled individually. Still, metformin is the first-line optimal oral agent to manage T2DM. Physicians need to be aware of the benefits of such therapies with respect to the CV outcomes and impact. European Association for the Study of Diabetes and the American Diabetes Association formed an updated consensus statement on how to manage hyperglycaemia in patients with type 2 diabetes. There key point is that the selection of medication added to metformin is based on patient preference and clinical characteristics, including presence of CVD, heart failure and kidney disease.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA